Begin main content

Vectibix for Left Sided Metastatic Colorectal Cancer — Details

Project Number pCODR 10118
Brand Name Vectibix
Generic Name Panitumumab
Strength 20 mg/mL
Tumour Type Gastrointestinal
Indication Left Sided Metastatic Colorectal Cancer
Funding Request In combination with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS
Review Status Under Review
Pre Noc Submission No
NOC Date August 31, 2015
Manufacturer Amgen Canada Inc.
Submitter Amgen Canada Inc.
Submission Date September 8, 2017
Submission Deemed Complete September 15, 2017
Submission Type New Indication
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ September 22, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.